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STATE-OF-THE-ART PAPERRSTATE-OF-THE-ART PAPER659Peripartum CardiomyopathyUri Elkayam
Peripartum cardiomyopathy is a pregnancy-associated myocardial disease that results in
marked left ventricular systolic dysfunction. Elkayam reviews the incidence, risk factors,
treatments, and outcomes of peripartum cardiomyopathy. Risk factors for peripartum
cardiomyopathy include older maternal age, history of hypertension, multiple pregnancies,
and African-American background. Potential complications include severe heart failure,
cardiogenic shock, cardiopulmonary arrest, thromboembolic complications, and death.
Treatment needs to consider the risk of teratogenic effects and issues related to breast-feeding.SPECIAL ARTICLE SPECIAL ARTICLE
671ates of International Participation in
Clinical Cardiovascular Trials Sponsored by the NHLBIEsther S. H. Kim, Thomas P. Carrigan, Venu Menon
Kim and colleagues investigated the international enrollment in National Institutes of
Health–sponsored clinical cardiovascular randomized controlled trials. Of 24 studies
that met the inclusion criteria, 19 trials including 151,682 patients had international
participation (IP), with a median IP rate of 9.5% (range 0% to 100%). Rates of non-U.S.
enrollment were high in coronary artery disease trials (50%), high-risk trials, and trials
testing acute interventions, such as for myocardial infarction. The authors question
whether this is desirable given both ethical and financial considerations and the
applicability of the results to U.S. populations.
Editorial Comment: Robert M. Califf, Robert A. Harrington, p. 677(continued on page A-26)
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681isk of Cerebrovascular Accident With AF Ablation
Varies With Type of Ablation CatheterClaudia Herrera Siklo´dy, Thomas Deneke, Mélèze Hocini, Heiko Lehrmann, Dong-In Shin,
Shinsuke Miyazaki, Susanne Henschke, Peter Fluegel, Jochen Schiebeling-Römer, Paul M. Bansmann,
Thomas Bourdias, Vincent Dousset, Michel Haïssaguerre, Thomas Arentz
Siklo´dy and colleagues compared the rates of periprocedural intracranial embolic events in
patients undergoing pulmonary vein isolation for atrial fibrillation (AF) with 3 different types
of ablation catheters: 1) conventional irrigated radiofrequency (RF); 2) cryoballoon; and
3) multielectrode duty-cycled RF pulmonary vein ablation catheter (PVAC). Patients were
not randomized, but were treated at 3 hospitals using similar protocols with hospitals chosen
based on their experience with a particular catheter. Total procedure times were shortest with
the PVAC. Neurological examination was normal in all patients before and after ablation, but
post-procedural magnetic resonance imaging detected new embolic lesions in 37% of PVAC
patients compared with 7.4% of RF and 4.3% of cryoballoon patients. These results suggest
that the PVAC catheter is associated with a significantly higher incidence of intracranial
embolic events and the need for further study.Editorial Comment: Jonathan S. Steinberg, Suneet Mittal, p. 689INTERVENTIONAL CARDIOLOGY
692eta-Analysis Suggests Culprit Vessel PCI Only
for STEMI Patients With Multivessel DiseasePieter J. Vlaar, Karim D. Mahmoud, David R. Holmes, Jr, Gert van Valkenhoef, Hans L. Hillege,
Iwan C. C. van der Horst, Felix Zijlstra, Bart J. G. L. de Smet
Vlaar and colleagues investigated the best strategies for patients with ST-segment
elevation myocardial infarction (STEMI) found to have multivessel disease (MVD).
Three percutaneous coronary intervention (PCI) strategies were compared for MVD in
STEMI patients from 4 prospective and 14 retrospective studies, involving 40,280
patients. The results showed significantly lower short-term mortality with staged PCI
compared with culprit vessel only or multivessel PCI. This meta-analysis supports current
guidelines discouraging performance of multivessel primary PCI for STEMI during the
initial procedure, but suggests the need for complete revascularization in these patients.
Editorial Comment: John A. Bittl, p. 712(continued on page A-27)
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704ubgroup Analysis From the HORIZONS-AMI Trial Shows
Staging PCI Is Safer for STEMI Patients With Multivessel DiseaseRan Kornowski, Roxana Mehran, George Dangas, Eugenia Nikolsky, Abid Assali, Bimmer E. Claessen,
Bernard J. Gersh, S. Chiu Wong, Bernhard Witzenbichler, Giulio Guagliumi, Dariusz Dudek, Martin Fahy,
Alexandra J. Lansky, Gregg W. Stone, for the HORIZONS-AMI Trial Investigators
Kornowski and colleagues compared primary percutaneous coronary intervention (PCI) of
the culprit and nonculprit lesions with PCI of only the culprit lesion and later intervention on
nonculprit lesions in patients with ST-segment elevation myocardial infarction (STEMI) and
multivessel disease (MVD). Approximately 1 of 5 subjects enrolled in the HORIZONS-AMI
(Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction)
trial had MVD. Patients were categorized into a single PCI strategy versus staged PCI. The
rate of 1-year mortality was 9.2% in patients who underwent multivessel primary PCI
compared with 2.3% in those who underwent a staged procedure. The mortality advantage
favoring staged PCI was consistent for several subgroups and endpoints. These results
confirm the superiority of a deferred angioplasty strategy of nonculprit lesions in STEMI
patients.Editorial Comment: John A. Bittl, p. 712INTERVENTIONAL CARDIOLOGY715Initial Experience With TAVI in Patients With a Mitral ProsthesisJia Lin Soon, Jian Ye, Samuel V. Lichtenstein, David Wood, John G. Webb, Anson Cheung
Transcatheter aortic valve implantation (TAVI) for aortic stenosis in patients with mitral
prostheses is technically challenging because of the interaction between the aortic and mitral
prosthesis at the anatomic aorto-mitral continuity. Soon and colleagues report on their
experience with 10 patients with a previous mitral valve replacement who were declined
conventional surgery and underwent TAVI. All valves were successfully implanted, with no
30-day mortality or mitral prosthetic dysfunction. There were no valve-related deaths at a
mean follow-up of 12 months, and there were significant improvements in New York Heart
Association functional class and transvalvular gradients. The mitral bioprosthetic strut
predisposes to device “shift” during deployment, and the likelihood of this occurring with
various types of valves is discussed.(continued on page A-32)
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CHEART RHYTHM DISORDERS722Intermittent Early Repolarization May Be Linked to Sudden Cardiac DeathNicolas Derval, Christopher S. Simpson, David H. Birnie, Jeffrey S. Healey, Vijay Chauhan,
Jean Champagne, Martin Gardner, Shubhayan Sanatani, Raymond Yee, Allan C. Skanes, Lorne J. Gula,
Peter Leong-Sit, Kamran Ahmad, Michael H. Gollob, Michel Haïssaguerre, George J. Klein,
Andrew D. Krahn
Derval and colleagues evaluated the prevalence and characteristics of early repolarization in
patients in CASPER (Cardiac Arrest Survivors with Preserved Ejection Fraction Registry).
A total of 100 patients with apparently unexplained cardiac arrest (UCA) and preserved
ejection fraction underwent extensive clinical and genetic testing. Early repolarization was
defined as 0.1 mV elevation of the QRS-ST junction (J point) with terminal QRS slurring
r notching in at least 2 contiguous leads. Early repolarization was found in 19 patients,
ncluding 14% of those with a diagnosis that explained their cardiac arrest and 23% of
hose with idiopathic ventricular fibrillation. J-wave amplitude was fluctuant on serial
lectrocardiograms (ECGs); at least 1 ECG did not have early repolarization in 58% of
atients. Early repolarization is present in a significant proportion of patients with UCA
ut may be intermittent.CARDIAC RESYNCHRONIZATION THERAPY
729RT-D Significantly Reduces the Risk of
Heart Failure Hospitalizations in Patients With LBBBIlan Goldenberg, W. Jackson Hall, Christopher A. Beck, Arthur J. Moss, Alon Barsheshet, Scott McNitt,
Slava Polonsky, Mary W. Brown, Wojciech Zareba
Goldenberg and colleagues evaluated the effect of cardiac resynchronization therapy with a
defibrillator (CRT-D) on the occurrence of recurring heart failure events (HFEs) following a
first post-implantation HFE. Using data from MADIT-CRT (Multicenter Automatic
Defibrillator Implantation Trial with Cardiac Resynchronization Therapy), CRT-D was
associated with a significant reduction in the risk of a first HFE (hazard ratio: 0.54) and also
significantly reduced the risk of a second HFE in those who suffered a first HFE. Benefits
were limited to those with a left bundle branch block (LBBB). These results suggest that
trials of CRT-D focusing on only first events may underestimate the benefit of this therapy
for preventing HFEs.
Editorial Comment: Frieder Braunschweig, p. 738(continued on page A-33)
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740rognostic Significance of Quantitative
Myocardial Blood Flow With 82Rb PET ImagingMaria C. Ziadi, Robert A. deKemp, Kathryn A. Williams, Ann Guo, Benjamin J. W. Chow,
Jennifer M. Renaud, Terrence D. Ruddy, Niroshi Sarveswaran, Rebecca E. Tee, Rob S. B. Beanlands
Ziadi and colleagues investigated the additional clinical value of myocardial flow reserve
(MFR) quantification using Rubidium-82 (82Rb) positron emission tomography (PET)
maging compared with relative myocardial perfusion imaging (MPI) in over 700 patients.
low MFR was predictive of cardiac death and myocardial infarction in both subjects with a
ormal summed stress score (SSS) or an abnormal SSS. In the adjusted Cox model, MFR
as an independent predictor of hard events (hazard ratio [HR]: 3.3) and major cardiac
dverse events (HR: 2.5). MFR quantified using 82Rb PET can predict hard cardiac events
independent of SSS and other parameters.Editorial Comment: Frank M. Bengel, p. 749ANTIPLATELET THERAPY752Expression of MRP4 Modulates Aspirin EffectivenessTeresa Mattiello, Raffaella Guerriero, Lavinia Vittoria Lotti, Elisabetta Trifirò, Maria Pia Felli,
Alessandro Barbarulo, Bruna Pucci, Paola Gazzaniga, Carlo Gaudio, Luigi Frati, Fabio M. Pulcinelli
Multidrug resistance protein-4 (MRP4) is an organic anion unidirectional transporter; aspirin
is an organic anion and could be a substrate for MRP4. Mattiello and colleagues investigated
the role of MRP4 in modulating aspirin action on human platelet cyclooxygenase (COX)-1.
Intracellular aspirin concentrations and drug COX-1 activity were evaluated in platelets
obtained from healthy volunteers and post-coronary artery bypass grafting (CABG) patients.
The results indicate that direct elimination of aspirin from the cytosol via MRP4-mediated
transport limits the drug’s ability to inhibit platelet function. MRP4 overexpression is directly
linked to aspirin-reduced cell entrapment, and thereby to increased thromboxane-B2
production and aspirin resistance, as is found in post-CABG patients.
Editorial Comment: John W. Eikelboom, Graeme J. Hankey, p. 762(continued on page A-34)
AUGUST 9, 2011 (continued) A-34pEXPEDITED PUBLICATION765Mixed Results With Baroreflex Activation Therapy for Resistant HypertensionJohn D. Bisognano, George Bakris, Mitra K. Nadim, Luis Sanchez, Abraham A. Kroon, Jill Schafer,
Peter W. de Leeuw, Domenic A. Sica
The Rheos Pivotal Trial evaluated the safety and efficacy of baroreflex activation therapy
(BAT) in patients with resistant hypertension. This device uses a subcutaneously planted
pulse generator with 2 tunneled leads to the bilateral carotid baroreceptors. A total of 265
subjects with a baseline systolic blood pressure (SBP) 160 mm Hg underwent the procedure
and were then randomized to BAT On or Off for the first 6 months, after which all subjects
received active therapy. The trial met the endpoints of BAT safety, device safety, and
sustained efficacy, defined as a reduction at 12 months of at least 10 mm Hg and at least 50%
of the reduction seen at 6 months. However, it did not meet the endpoints for acute
responders, with 54% of those assigned to device On achieving a 10 mm Hg drop compared
with 46% of those programmed to Off, and a higher than expected rate of device implant
complications. A protocol-specified ancillary analysis showed that significantly more On
subjects achieved SBP 140 mm Hg at 6 months. Further trials of the device are in
rogress.
